Skip to main content

Table 1 The clinical and laboratory characteristics of SSc patients

From: Hypomethylation and overexpression of ITGAL (CD11a) in CD4+ T cells in systemic sclerosis

Patients/Age/Sex

SSc subtype

Disease duration

Clinical features

Current treatment

ANA type

MRTSS

SDAI

1/52/F

lcSSc

2 years

A, B, R

Prednisone, 10 mg/day

Nucleolar

26

3.5

2/45/M

dcSSc

2.5 years

A, E

Prednisone, 12.5 mg/day

Anti-Scl70

33

4

3/43/F

lcSSc

3.5 years

E, M, R

None

ACA

22

2

4/45/M

dcSSc

2.5 years

M, PF, R

Chinese herbal medicines

Anti-RNP

25

3

5/32/F

dcSSc

0.5 years

C, R

None

Anti-Scl70

14

2

6/46/F

dcSSc

1 years

C, E, R

Prednisone, 7.5 mg/day

Nucleolar

39

3.5

7/49/F

lcSSc

2.5 years

A, PF, R

Methylprednisone, 8 mg/day

Nucleolar

28

4.5

8/44/M

dcSSc

2 years

A, E

Methylprednisone, 4 mg/d

Anti-PM-1

18

2

9/47/M

dcSSc

2 years

A, B, PF, R

Chinese herbal medicines

Anti-Scl70

29

5

10/37/F

dcSSc

3 years

A, B, E, PHT, R

Prednisone, 12.5 mg/day

Anti-Scl70

45

9

11/39/M

lcSSc

1.5 years

E, R

None

none

21

2

12/41/F

lcSSc

2 years

A, B, E

Prednisone, 15 mg/day

ACA

27

3.5

13/57/F

dcSSc

2 years

A, E, PF, R

Prednisone, 12.5 mg/day

ACA

40

6

14/43/M

dcSSc

2 years

E, PF, R

None

ACA

36

3

15/35/F

dcSSc

0.5 years

C, E, R

Prednisone, 7.5 mg/day

ACA

22

3

16/36/M

lcSSc

2 years

C, M, R

None

ACA

19

2.5

17/40/F

dcSSc

3 years

A, E, R

Chinese herbal medicines

Anti-RNP

22

4

18/39/M

dcSSc

2.5 years

A, E, M, R

None

Nucleolar

27

6

  1. F, Female; M, Male; dcSSc, Diffuse cutaneous systemic sclerosis; lcSSc, Limited cutaneous systemic sclerosis; A, Arthritis; C, Calcinosis; B, Bowel involvement; E, Esophageal involvement; M, Myositis; PF, Pulmonary fibrosis; PHT, Pulmonary hypertension; R, Reynaud’s phenomenon; ACA, Anticentromere antibodies; MRTSS, Modified Rodnan total skin score; SDAI, Valentini scleroderma disease activity index; ANA type, Anti-nuclear antibodies type; Anti-Scl70, Anti-DNA-topoisomerase I antibodies; Anti-RNP, Anti = nuclear ribonucleic acid protein atibodies; Anti-PM-1, Anti-polymyositis-1 antibodies.